| Popis: |
The multiplicity of experimental models of angiogenesis in vitro and in vivo complicates the choice of a straightforward strategy to accurately identify the anti-angiogenic potential of a natural or synthetic compound with antitumoral activity. In the absence of such consensus, it is clear that the demonstration of an activity lies in the use of several models, both in vitro and in vivo. A rapid overview of the most currently used models, especially in vitro, is presented, with an emphasis on their limitations. Several examples of research strategies for identifying antitumoral anti-angiogenic compounds are used in illustration. |
